Ocular Manifestations in Rheumatic Diseases

Sponsor

Lawson Health Research Institute (Other)

Overall Status

Completed

CT.gov ID

NCT03753893

Collaborator

(none)

5,000

Enrollment

102

Actual Duration (Months)

Study Details

Study Description

Brief Summary

This is a search strategy for determining the prevalence of ocular complications in inflammatory rheumatic diseases for the purposes of a meta analysis.

Condition or Disease	Intervention/Treatment	Phase
Uveitis Conjunctivitis Keratoconjunctivitis Sicca Xerophthalmia Eye Hemorrhage Optic Neuritis Papilledema Orbital Diseases Retinal Vein Occlusion Retinal Artery Occlusion Macular Edema Retinitis Chorioretinitis Iridocyclitis Scleritis Choroid Hemorrhage Blindness Amaurosis Fugax	Other: No intervention used

Detailed Description

For the purposes of determining the prevalence of ocular complications in inflammatory rheumatic diseases, the following search terms were used: conjunctivitis, keratoconjunctivitis sicca, xerophthalmia, uveitis, eye hemorrhage, optic neuritis, papilledema, orbital disease, retinal artery/vein occlusion, macular edema, retinitis, chorioretinitis, scleritis, iridocyclitis, choroid hemorrhage, blindness and amaurosis fugax.

These terms were searched in the context of a corresponding inflammatory disease on Medline, Cochrane and Web of Science from their inception (1966, 1991 and 1990 respectively) until the point of study completion.

Studies were included if they provided numerical data of the prevalence or incidence of ocular manifestations in an inflammatory rheumatic disease. Studies were excluded if they were review articles, case reports where all patients experienced the same ocular comorbidity, if different comorbidities were not grouped independently, and if the study reported on fewer than 20 patients. When the same study cohort was used in more than one analysis, the most recent or largest sample-size study was included. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist was used to assess the quality of cohort, case-control, and cross-sectional studies.

Study Design

Study Type:

Observational

Actual Enrollment :

5000 participants

Observational Model:

Ecologic or Community

Time Perspective:

Retrospective

Official Title:

Prevalence of Ocular Manifestations in Inflammatory Rheumatic Diseases

Actual Study Start Date :

May 1, 2013

Actual Primary Completion Date :

Apr 1, 2021

Actual Study Completion Date :

Nov 1, 2021

Outcome Measures

Primary Outcome Measures

Prevalence of ocular manifestations of inflammatory rheumatic diseases [data is collected once per year up to 2020]
Prevalence of ocular manifestations of inflammatory rheumatic diseases